The statements below are read from SHELTER PHARMA LIMITED’s filed results, 3 filed quarters and 9 fiscal years on record, standalone basis. Price-linked ratios are computed at the last close, sector medians across the served universe, ownership from the shareholding pattern, and any cell whose input isn’t on record shows a dash, never an estimate.
Latest: H2 FY25-26 · filed May 28, 2026 · audited
This company files half-yearly statements with the exchange — each column is a six-month period; discrete quarterly figures are not published.
| ₹ Cr | H2 FY25Mar 2025 | H1 FY26Sep 2025 | H2 FY26Mar 2026Latest | YoYlatest |
|---|---|---|---|---|
| Sales | 26.6 | 33.3 | 39.8 | +49.8% |
| 21.4 | 27.0 | 33.4 | +55.7% | |
| Operating profit | 5.17 | 6.26 | 6.47 | +25.0% |
| OPM % | 19.4% | 18.8% | 16.2% | -3.2 pp |
| Other income | 0.00 | 0.00 | 0.01 | +229.4% |
| Interest | 0.06 | 0.06 | 0.05 | -22.0% |
| Depreciation | 0.17 | 0.19 | 0.22 | +29.8% |
| Profit before tax | 4.95 | 6.01 | 6.21 | +25.6% |
| Tax % | 25.2% | 25.2% | 27.1% | +1.9 pp |
| Net profit | 3.70 | 4.50 | 4.53 | +22.3% |
| EPS (₹) | 3.20 | 3.89 | 2.69 | -15.9% |
No results filing with a recorded time yet — reactions appear from the first quarter whose announcement we timestamped (May 2026 onward), on the session the market could trade it.
